Bicycle Therapeutics (STU:50BA) ROCE %: -38.61% (As of Mar. 2026)


STU:50BA Bicycle Therapeutics PLC STU:50BA
54 GF Score
Price €3.48
GF Value €13.05
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics ROCE %?

Bicycle Therapeutics STU:50BA +0.58% 54 ROCE % is -38.61% as of Mar. 2026. GuruFocus rates STU:50BA with a GF Score™ of 54/100 and a GF Value™ of €13.05 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bicycle Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -38.61%.

Bicycle Therapeutics  (STU:50BA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bicycle Therapeutics ROCE % Related Terms

Bicycle Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Bicycle Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicycle Therapeutics ROCE % Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -22.91 -28.69 -39.38 -24.68 -26.41

Bicycle Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.33 -38.69 -32.19 -11.13 -38.61
STU:50BA
54GF Score
Bicycle Therapeutics PLC STU:50BA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicycle Therapeutics ROCE % Calculation

Bicycle Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-186.686/( ( (913.809 - 64.205) + (612.828 - 48.664) )/ 2 )
=-186.686/( (849.604+564.164)/ 2 )
=-186.686/706.884
=-26.41 %

Bicycle Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-209.692/( ( (612.828 - 48.664) + (564.323 - 42.289) )/ 2 )
=-209.692/( ( 564.164 + 522.034 )/ 2 )
=-209.692/543.099
=-38.61 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -38.61% mean?
Bicycle Therapeutics (STU:50BA) has a ROCE % of -38.61% as of Mar. 2026.
Is Bicycle Therapeutics' ROCE % too high?
Bicycle Therapeutics' current ROCE % is -38.61%. Overall, Bicycle Therapeutics has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' ROCE % compare to ABEO and DMAC?
Bicycle Therapeutics' ROCE % of -38.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Bicycle Therapeutics's current ROCE % is -38.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (STU:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €13.05, compared to a current price of €3.48 — trading 73.3% below its estimated fair value. The current ROCE % is -38.61%. Bicycle Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Bicycle Therapeutics (STU:50BA), the current ROCE % is -38.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bicycle Therapeutics (STU:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.48 is trading 73.3% below its estimated GF Value™ of €13.05. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for STU:50BA:

  • ROCE %: -38.61%
  • GF Value™: €13.05 vs. price of €3.48 (73.3% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the STU:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
54GF Score

Get the complete analysis for STU:50BA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.48
Price
€13.05
GF Value